Form 4: Denali Therapeutics COFO Sells Shares for Tax Obligations

Denali Therapeutics' Chief Financial Officer and Secretary, Alexander O. Schuth, sold 17,218 shares of common stock to cover tax liabilities from vested restricted stock units.

Summary

• Alexander O. Schuth, COFO and Secretary of Denali Therapeutics Inc. (DNLI), reported a transaction involving the company's common stock.
• On January 6, 2026, Schuth sold 17,218 shares of Denali Therapeutics common stock at a price of $16.5 per share.
• The sale was conducted to satisfy tax obligations arising from the settlement of previously vested Restricted Stock Units (RSUs).
• Following this transaction, Schuth directly beneficially owns 282,828 shares, which includes 141,100 unvested RSUs.
• Additionally, Schuth indirectly beneficially owns 523,749 shares through The Schuth Family Trust, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The transaction is a routine sale to cover tax obligations from vested RSUs, which is a neutral event for the company's operational performance. While it reduces direct insider ownership, it's a common practice and not indicative of a negative outlook on the company.

Positives

• The underlying event, the vesting of Restricted Stock Units (RSUs), indicates a positive compensation event for the executive.

Negatives

• The direct beneficial ownership of common stock by a key executive decreased by 17,218 shares.

Future Outlook

N/A

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape. It reflects an individual executive's compensation and tax planning.

Related Party Transactions

• The indirect beneficial ownership of 523,749 shares is held by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person, Alexander O. Schuth, serves as trustee. This constitutes a related party holding.

Stakeholder Impact

• Shareholders: A slight reduction in direct insider ownership, but the underlying RSU vesting indicates executive compensation alignment. The sale is for tax purposes, a common practice, and not necessarily a signal of lack of confidence.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider sale by a key executive to cover tax obligations associated with vested restricted stock units. Such transactions are common and generally not indicative of a change in the company's fundamental prospects or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Trading, Stock Sale, Tax Obligations, Restricted Stock Units, RSUs, Executive Compensation, Alexander O. Schuth